T cell activation is the net product of competing positive and negative signals transduced by regulatory molecules on antigen presenting cells (APC) binding to corresponding ligands on T cells. Having previously identified DC-HIL as a receptor expressed by APC that contains an extracellular immunoglobulin-like domain, we postulated that it plays a role in T cell activation.
Introduction
to exaggerated autoimmunity since PD-1 knockout mice develop splenomegaly, increased numbers of B and myeloid cells, increased serum IgG and IgA, and a lupus-erythematosus-like disease with age. 19, 20 These mice are also markedly susceptible to Ag-induced experimental autoimmune encephalomyelitis (EAE). 19, 20 BTLA-knockout mice do not exhibit developmental T or B cell defects, but their lymphocytes have heightened responses to anti-CD3 Ab and to antiIgM Ab; 8 these mice are also prone to developing EAE. 8 In the case of the Tim-3 pathway, its blockade by mAb, Fc-fused soluble receptor, or gene disruption leads to exacerbated Th1-mediated autoimmune diabetes mellitus in NOD mice. 10, 11 T cell expression of PD-1, BTLA or Tim-3 resembles CTLA-4 in that it is not constitutive, but induced by activation. 21 Moreover, the costimulation delivered by each appears to be mediated through the TCR. 12 By contrast, expression of PD-1, BTLA, Tim-3, or their ligands differ from CTLA-4 in that it is not restricted to T cells, but expressed more widely to include B cells and APC. Indeed, some of these ligands (PD-L1 and PD-L2) are also expressed in nonlymphoid tissues. 12 Such broad expression profiles suggest that these molecules can modulate immune responses in secondary lymphoid organs and peripheral tissues, 6 consistent with the observation that IFN-γ can induce expression of PD-1 ligands on nonlymphoid cells. 13 Previously, we identified DC-HIL as a highly glycosylated type I transmembrane protein of 125 and 95 KDa, containing an extracellular Ig-like domain. 22 We also showed that DC-HIL is expressed constitutively at high levels on the surface of bone marrow-derived dendritic cells (BM-DC) (see supplemental data #1) and at lower levels on macrophages 22 and that its 
Materials and Methods

Mice and cell culture
Production of DC-HIL-Fc protein
The Fc-fusion proteins (DC-HIL-Fc, its mutants, and Fc alone) were produced in COS-1 cells and purified as described previously.
22
Isolation of T cells and binding of DC-HIL Following manufacturer's recommendations, CD3
+ , CD4 + , and CD8 + T cells were purified from spleen cells of BALB/c mice using pan T cell, CD4 + , and CD8 + T cell isolation kits (Myltenyi Biotec, Auburn, CA), respectively. Contact hypersensitivity assays BALB/c mice (n = 5) were sensitized for contact hypersensitivity (CH) on day 0 by painting 2% oxazolone (Ox) (Sigma) in acetone-olive oil (4:1 in volume) on shaved abdominal skin (sensitization). 26 Mice were challenged on day 6 by painting 1% Ox and solvent control to right and left ears, respectively (elicitation). Thereafter, CH was assessed daily through day 12 by measuring ear thickness and calculating changes in ear swelling (thickness of right ear minus thickness of control left ear). 27 Different panels of mice were injected intraperitoneally with DC-HIL-Fc or the control hIgG (10 mg/kg each) or DPBS on days -1, 1 and 3 (before and after sensitization) or on days 5, 7 and 9 (before and after elicitation). Student's t test was used to determine statistically significant differences in ear swelling responses. Generation of mutants DC-HIL-Fc carrying the RAA mutant (replacement of RGD sequence with RAA) was generated as before. 22 PRR and PKD mutants (lacking a region between amino acids 301 to 334 and 230 to 355, respectively) were produced by PCR-based mutagenesis.
Resulting nucleotides coding extracellular domains of DC-HIL mutants were inserted in-frame to the coding sequence of the human IgG 1 Fc in pSecTagA plasmid (Invitrogen) using 3 restriction enzyme sites (from the 5'-end, HindIII, EcoRI, and XbaI). The mutant DC-HIL-Fc proteins were produced as described previously. 22 The yield for each mutant was very similar to the wild-type and all preparations showed a single band reactive to anti-human IgG Ab.
Results
Activated T cells express ligands of DC-HIL
To study the function of DC-HIL, we created soluble DC-HIL receptors (DC-HIL-Fc) consisting of the extracellular domain fused with the Fc portion of human IgG 1 (hIgG) 22 and used FACS analysis to examine binding to T cells. DC-HIL-Fc did not bind to T cells freshly isolated from spleen of naive mice, but did so after the T cells were activated by concanavalin A (Fig. 1A) or by immobilized anti-CD3 Ab (Fig. 1B) . Binding was noted as early as a day after stimulation
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From and lasted for at least 3 days. We also examined binding to T cell subsets ( Because ligation of CD28 on T cells amplifies TCR-mediated T cell activation, 29 we questioned whether CD28 costimulation can rescue DC-HIL-induced inhibition (Fig. 2F ). Anti-CD28 mAb (in increasing doses) was immobilized on microwells precoated with DC-HIL-Fc or hIgG (10 µg/ml each) and anti-CD3 Ab (0.3 µg/ml). Purified CD4 + T cells were cultured in coated wells and activation status determined by 3 H-thymidine incorporation. In the absence of anti-CD28 mAb, DC-HIL-Fc again markedly inhibited T cell activation (Fig. 2F) . However, such inhibition was overcome by addition of anti-CD28 mAb in a dose-dependent manner, with 3 µg/ml anti-CD28 mAb completely rescuing DC-HIL-Fc-induced inhibition.
We also examined whether DC-HIL exerts inhibitory effects on previously activated T cells (Figs. 2G-J). Spleen cells isolated from BALB/cTac-TgN(DO11.10)-Rag2 tm1 mice 23 bearing a transgene encoding TCR specific for the ovalbumin peptide (OVA 323-339 ) 25 were activated by adding the OVA peptide to the culture. Activated CD4 + T cells were isolated and reactivated with immobilized anti-CD3 Ab and DC-HIL-Fc or control Ig. DC-HIL markedly inhibited T cell proliferation (Fig. 2G ) in response to anti-CD3 Ab and abrogated IL-2 production (Fig. 2H) . We also titrated the inhibitory capacity of DC-HIL against the reactivation, as described previously (Figs. 2I and J). Similar to effects on naive T cells (Fig.   2E ), DC-HIL-Fc strongly inhibited T cell proliferation at 5 µg/ml (Fig. 2I ) and reduction of IL-2 production was even greater (Fig. 2J) . These results indicate that the putative T cell ligand for DC-HIL mediates a potent signal that can inhibit activation of primary as well as secondary T cell responses.
Binding of DC-HIL to T cells induces cell cycle arrest
Since PD-1-mediated signals prevented anti-CD3 Ab-treated T cells from entering the cell cycle, 13, 15 we questioned whether inhibition of T cell activation by DC-HIL-Fc is similarly achieved. CD4 + T cells were cultured in wells coated with anti-CD3 Ab plus DC-HIL-Fc or control hIgG; at different time points thereafter, the T cells were assayed for asynchronous cell division using CFSE labeling and FACS analysis (Fig. 3A) . For anti-CD3 Ab and hIgG-treated cells, the number of cell divisions increased 6-fold and the frequency of divided cells increased up to 51%. DC-HIL-Fc-treated T cells also divided several times, but at a lesser frequency ( To more rigorously examine effects of soluble DC-HIL-Fc on T cell activation, we employed an in vitro antigen presentation assay, in which BM-DC were pulsed with OVA peptide (OVA 323-339 ) 24 and allowed to activate CD4 + T cells prepared from unprimed (Fig. 4F ). Increasing numbers of these transfected DC were pulsed with OVA peptide and then allowed to activate a constant number of CD4 + T cells purified from TacTgN(DO11.10)-Rag2 tm1 mice. T cell activation was assayed by IL-2 production (Fig. 4G ). At every dose tested, DC-HIL siRNA-transfected DC were more potent activators of OVA-specific T cells, compared to control siRNA-DC. Enhanced activation was also affirmed by a higher frequency of CD69 + T cells (92.6% vs. 81.7%) in co-culture (Fig. 4H) .
In vivo injection of soluble DC-HIL augments contact hypersensitivity (CH) responses
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To ascertain the biological significance of the DC-HIL/DC-HIL-L pathway, we examined effects of soluble DC-HIL on CH, an experimental model of delayed-type, T cell-mediated skin inflammation. BALB/c mice were sensitized by topical application of the hapten, oxazolone (Ox), at a dose of 2% on abdominal skin (day 0) and then challenged/elicited by painting ears with 1% Ox (day 6) (Fig. 5) . Mice in different panels were injected intraperitoneally with DC-HIL-Fc, hIgG, or PBS every other day on 3 occasions either starting a day before sensitization (Fig. 5A ) or a day before elicitation (Fig. 5B) . Ear swelling was measured and change in ear thickness calculated. Ear swelling in mice treated with DC-HIL-Fc just before and after haptensensitization was no different from that of mice injected with control hIgG (Fig. 5A ). By contrast, mice injected with DC-HIL-Fc just before and after hapten-elicitation displayed significantly greater ear swelling that persisted longer (up to 6 days after elicitation), compared to those of control mice (Fig. 5B) . Histological analysis of Ox-painted ear skin revealed a marked increase in skin thickness and number of skin-infiltrating leukocytes in mice treated with DC-HIL-Fc, but not control hIgG (Fig. 5C ).
To determine the activation status of T cells in Ox-sensitized mice injected with DC-HILFc, we compared draining lymph nodes (LN) and LN cells of DC-HIL-Fc-treated vs. control mice 2 days after Ox challenge, which was the time of greatest ear swelling. LN of DC-HILtreated mice were thrice larger than hIgG-treated mice, contained thrice the number of cells (Fig.   6A ) and displayed 3-fold greater T cell proliferation in the absence of stimuli (Fig. 6B) . We also compared the frequency of CD4 + , CD8 + , or B220 + LN cells (Fig. 6C) 
PKD domain is required for the inhibitory function of DC-HIL on T cell activation We
reported previously that the extracellular domain of DC-HIL contains: RGD motif required for integrin-mediated cell adhesion; Ig-like polycystic kidney disease (PKD) domain; 30 and a proline-rich region (PRR) involved in protein-protein interactions. 31 To determine whether some or all are required for the inhibitory function of DC-HIL on T cell activation, we created extracellular domains of mutant DC-HIL lacking PKD or PRR, or containing RAA (instead of RGD), and fused these mutants to the IgG-Fc (Fig. 7A) . Purity of the mutants was quite high (similar to the wild-type), as judged by SDS-PAGE/Coomassie blue staining (Fig. 7B) . We then examined the capacity of mutants to inhibit T cell activation by titrating a given dose of mutant (or wild-type) DC-HIL-Fc to increasing doses of anti-CD3 Ab (Fig. 7C) . The inhibitory activity of wild-type DC-HIL-Fc (5 µg/ml) decreased progressively with increasing doses of anti-CD3
Ab. The titration curve of the RAA mutant was similar to the wild-type. The PRR-deficient mutant showed only minimally reduced inhibitory activity at a dose of 0.3 µg/ml anti-CD3 Ab.
By contrast, the PKD-deficient mutant almost completely lost inhibitory activity at each dose of anti-CD3 Ab tested. We also compared mutants vs. wild-type with respect to T cell binding (Fig. 7D) . RAA and PRR mutants bound to T cells as efficiently as the wild-type, whereas the PKD mutant failed to bind to T cells (correlating with results of inhibitory function).
These findings indicate that the Ig-like PKD domain is required for binding of DC-HIL to T cells and for its inhibitory function. By contrast, neither proline-mediated interaction nor RGDdependent cell adhesion appears necessary for DC-HIL's inhibitory function.
Discussion
Subtractive cDNA cloning of mouse XS52 DC minus J774 macrophages 22 led to our discovery of DC-HIL, also known as human nmb glycoprotein or gpnmb 32, 33 and rat osteoactivin. 34 The extracellular domain of DC-HIL contains a putative heparin-binding site, 35 many N-glycosylation sites, an RGD cell-adhesion motif, 36 a proline-rich region (involved in Oglycosylation 37 and/or protein-protein interactions 31 ), and an Ig-like PKD domain conserved among 14 repeats in the extracellular region of the PKD-susceptible gene product, polycystin-1. 30, 38 Moreover, we showed that DC-HIL is highly N-glycosylated, that it recognizes heparan sulfate especially on SVEC endothelial cells, 22 and that its RGD motif is responsible for integrin-mediated cell adhesion. 22 Our present study uncovered a new function for DC-HIL, as a potent inhibitor of TCR-induced T cell activation for both primary and secondary responses. An important task ahead is the identification of the DC-HIL-L on activated T cells.
Given our previous finding that DC-HIL recognizes heparin sulfate on endothelial cells, 22 we
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From -20-speculate heparan sulfate to be involved in binding of DC-HIL to DC-HIL-L. However, heparan sulfate alone is not likely to be the complete ligand since the PKD-deficient DC-HIL mutant we tested bound heparan sulfate but not activated T cells. Rather, we hypothesize the putative ligand to bear heparan sulfate plus a peptide with affinity for the PKD domain.
In summary, DC-HIL is a newly identified inhibitor of T cell activation that shares many common functional properties with PD-L1/PD-L2. Our discovery should prompt greater investigation on the role of DC-HIL/DC-HIL-L relative to other pathways regulating T cell activation since better understanding of these relationships and their biologic consequences may lead to the development of more effective T cell-based therapeutic applications.
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